Who is the CEO of Cardax, Inc.?

Mr. David G. Watumull is a business executive who currently serves as the CEO of Cardax, Inc..

What is the Revenue Growth of Cardax, Inc.?

Revenue growth data for Cardax, Inc. is currently unavailable.

What is Cardax, Inc. operating Margin?

Cardax, Inc. operating margin is 0.00% which shows how much profit CDXI earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Cardax, Inc. operate?

Cardax, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Cardax, Inc. revenue growth?

Revenue growth data for Cardax, Inc. is currently unavailable.

Cardax, Inc.

CDXI•PNK

Healthcare

Biotechnology

$0.001

$0.00(400.00%)

Cardax, Inc. (CDXI) Stock Overview

Explore Cardax, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for CDXIStats details for CDXI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for CDXIAnalyst Recommendations details for CDXI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

CEO

Mr. David G. Watumull

Employees

Headquarters

2800 Woodlawn Drive, Honolulu, HI

Founded

2013